Payment overview · 2025
General Payments
$138.03
3 reported records · 3 companies
Healthcare provider profile · identity verified
Dawn A Glenn, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CENTERVILLE, TN · NPI 1366474298
Verified facts
What the public records show
CMS Open Payments records show Dawn A Glenn, NP received $138.03 in general payments during 2025 across 3 reported records.
Novo Nordisk Inc accounted for 70.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $97.31 | 70.5% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $25.35 | 18.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.37 | 11.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $138.03 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $97.31 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $25.35 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 125 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
125 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 520 | 71 |
| Atorvastatin Calcium | Atorvastatin Calcium | 495 | 143 |
| Lisinopril | Lisinopril | 470 | 126 |
| Levothyroxine Sodium | Levothyroxine Sodium | 389 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 365 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 354 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 345 | 92 |
| Metformin Hcl | Metformin Hcl | 309 | 81 |
| Losartan Potassium | Losartan Potassium | 283 | 79 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 275 | 58 |
| Simvastatin | Simvastatin | 272 | 70 |
| Omeprazole | Omeprazole | 255 | 69 |
| Tramadol Hcl | Tramadol Hcl | 243 | 42 |
| Gabapentin | Gabapentin | 236 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 205 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 189 | 52 |
| Furosemide | Furosemide | 155 | 50 |
| Famotidine | Famotidine | 147 | 36 |
| Sertraline Hcl | Sertraline Hcl | 146 | 43 |
| Trazodone Hcl | Trazodone Hcl | 140 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 139 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 43 |
| Ozempic | Semaglutide | 125 | 22 |
| Meloxicam | Meloxicam | 123 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 120 | 19 |
| Carvedilol | Carvedilol | 119 | 37 |
| Ezetimibe | Ezetimibe | 119 | 31 |
| Jardiance | Empagliflozin | 119 | 21 |
| Eliquis | Apixaban | 118 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 111 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 107 | 37 |
| Alendronate Sodium | Alendronate Sodium | 106 | 28 |
| Methylprednisolone | Methylprednisolone | 106 | 102 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 100 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 99 | 31 |
| Allopurinol | Allopurinol | 95 | 30 |
| Lorazepam | Lorazepam | 85 | 14 |
| Potassium Chloride | Potassium Chloride | 82 | 28 |
| Repatha Sureclick | Evolocumab | 78 | suppressed |
| Clonazepam | Clonazepam | 77 | 11 |
| Buspirone Hcl | Buspirone Hcl | 75 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 75 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 15 |
| Pregabalin | Pregabalin | 75 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 17 |
| Valsartan | Valsartan | 69 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 22 |
| Promethazine Hcl | Promethazine Hcl | 66 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 16 |
| Atenolol | Atenolol | 65 | 15 |
| Montelukast Sodium | Montelukast Sodium | 59 | 17 |
| Xarelto | Rivaroxaban | 56 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 19 |
| Mirtazapine | Mirtazapine | 53 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 12 |
| Prednisone | Prednisone | 52 | 30 |
| Nystatin | Nystatin | 51 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 34 |
| Meclizine Hcl | Meclizine Hcl | 49 | 19 |
| Trulicity | Dulaglutide | 49 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 13 |
| Ondansetron Odt | Ondansetron | 47 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 43 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | 13 |
| Gemfibrozil | Gemfibrozil | 42 | suppressed |
| Glimepiride | Glimepiride | 41 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Mupirocin | Mupirocin | 39 | 29 |
| Ventolin Hfa | Albuterol Sulfate | 39 | suppressed |
| Fluconazole | Fluconazole | 38 | 24 |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | 12 |
| Spironolactone | Spironolactone | 37 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 34 | suppressed |
| Torsemide | Torsemide | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 21 |
| Estradiol | Estradiol | 31 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | suppressed |
| Levemir Flexpen | Insulin Detemir | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Cefdinir | Cefdinir | 29 | 26 |
| Ramipril | Ramipril | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 26 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | 15 |
| Ibuprofen | Ibuprofen | 25 | 11 |
| Invokana | Canagliflozin | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | 19 |
| Baclofen | Baclofen | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Ibu | Ibuprofen | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 15 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Bystolic | Nebivolol Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $138.03 · 3 records | Novo Nordisk Inc | Omnipod, Ozempic, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error